Merck's Strategy Transformation and Breakthrough Cancer Vaccine Data at ASCO

Each June, the American Society of Clinical Oncology (ASCO) hosts a conference that gathers physicians, researchers and the cancer community to share their latest research on treatments, technologies and more. 

The Fierce team is always on the ground at the ASCO meeting, and this year, Fierce Biotech’s Gabrielle Masson and Fierce Pharma’s Angus Liu covered the event. 

In this week's episode of "The Top Line," they discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. 

To learn more about the topics in this episode: 

• Akeso, Summit's Keytruda win draws 'explosive' interest at ASCO. But what does Merck think?
• ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
• ASCO: Cautious Big Pharmas double down on past wins—steering clear of radioligands and cell therapy

See omnystudio.com/listener for privacy information.